Tenofovir gel — Competitive Intelligence Brief

Tenofovir gel (Tenofovir gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor. Area: Infectious disease.

phase 3 Nucleotide reverse transcriptase inhibitor Reverse transcriptase Infectious disease Small molecule

Target snapshot

Tenofovir gel (Tenofovir gel) — National Institute of Allergy and Infectious Diseases (NIAID). Tenofovir gel works by inhibiting the replication of HIV by blocking the action of reverse transcriptase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tenofovir gel TARGET	Tenofovir gel	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Nucleotide reverse transcriptase inhibitor	Reverse transcriptase
Baraclude Tab.®	Baraclude Tab.®	Dong-A ST Co., Ltd.	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	Hepatitis B virus reverse transcriptase / HBV polymerase
Efavirenz or Nevirapine	Efavirenz or Nevirapine	University of Aarhus	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Atazanavir-Ritonavir/ Stavidine / Lamivudine	Atazanavir-Ritonavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Arm A: ABC+3TC+NNRTI	Arm A: ABC+3TC+NNRTI	Medical Research Council	marketed	Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor)	HIV reverse transcriptase
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate	Emtricitabine/rilpivirine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase
Genvoya Crushed Dose	Genvoya Crushed Dose	Johns Hopkins University	marketed	Antiretroviral combination (integrase inhibitor + NRTI + NtRTI + booster)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor class)

1. GlaxoSmithKline · 2 drugs in this class
2. IlDong Pharmaceutical Co Ltd · 1 drug in this class
3. Bristol-Myers Squibb · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
6. Sun Yat-sen University · 1 drug in this class
7. Jiangxi Kvvit Pharmaceutical Co., Ltd. · 1 drug in this class